Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 4/20 | 0.64 |
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2507401 | 0.93 | GFER (0.57) | GFERCASP6MAPTKMT2AMEN1 | |
| SCHEMBL7678698 | 0.83 | ALDH1A1 (0.49) | GFERCASP6MAPTKMT2AMEN1 | |
| SCHEMBL2480194 | 0.82 | CASP6 (0.45) | GFERCASP6MAPTKMT2AMEN1 | |
| SCHEMBL4670098 | 0.81 | USP2 (0.72) | GFERCASP6MAPTKMT2AMEN1 | |
| SCHEMBL27676396 | 0.81 | MAPT (0.53) | MAPTKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL188410 | 0.81 | MAPK1 (0.46) | GFERCASP6MAPTKMT2AMEN1 | |
| SCHEMBL188783 | 0.81 | NAMPT (0.51) | MAPTKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL17838736 | 0.80 | AKR1C3 (0.63) | GFERMAPTKMT2AMEN1USP2 | |
| SCHEMBL6160902 | 0.80 | MAPT (0.72) | MAPTKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL188776 | 0.80 | FASN (0.46) | GFERCASP6MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4352059-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2024-04-17 | — | — | EP | claimed |
| US-11939331-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-03-26 | — | — | US | claimed |
| US-20230002385-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-01-05 | — | — | US | claimed |
| WO-2022261160-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2022-12-15 | — | — | WO | claimed |
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | claimed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | claimed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | claimed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | claimed |
| EP-2970307-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2015135094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2015-09-17 | — | — | WO | claimed |
| WO-2012149567-A1 | KINASE INHIBITORS | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2012-11-01 | — | — | WO | claimed |
| CN-101547902-B | pyridine derivatives for treatment of metabolic disorders related with insulin resistance and hyperglycemia | PIRAMAL LIFE SCIENCES LTD | 2012-10-31 | — | — | CN | claimed |
| US-20110312970-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-12-22 | — | — | US | claimed |
| US-8030324-B2 | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia | PIRAMAL LIFE SCIENCES LTD. (IN) | 2011-10-04 | — | — | US | claimed |
| EP-2094663-B1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-01-26 | — | — | EP | claimed |
| US-20100022554-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | Piramal Enterprises Limited (IN) | 2010-01-28 | — | — | US | claimed |
| CN-101547902-A | Compounds for the treatment of metabolic disorders | NICHOLAS PIRAMAL INDIA LTD (IN) | 2009-09-30 | — | — | CN | claimed |
| EP-2094663-A2 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | Piramal Life Sciences Limited (IN) | 2009-09-02 | — | — | EP | claimed |
| WO-2008035305-A2 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | claimed |
| EP-0863757-B1 | 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2003-03-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | GFER 3584/4885CASP6 3138/4885MAPT 2234/4885 |
| US-20100022554-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | GPR119, INSR, PDXK | GFER 2933/4885CASP6 3252/4885MAPT 3034/4885 |
| US-20110312970-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | GPR119, INSR, PDXK | GFER 2933/4885CASP6 3252/4885MAPT 3034/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | GFER 3584/4885CASP6 3138/4885MAPT 2234/4885 |
| US-11939331-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | GFER 2459/4885CASP6 3400/4885MAPT 4197/4885 |
| US-20230002385-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | GFER 2459/4885CASP6 3400/4885MAPT 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.